Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “KRAS Mutant Solid Tumors”

52 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 52 results

Early research (Phase 1)Active Not RecruitingNCT06607185
What this trial is testing

The Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

Who this might be right for
Pancreatic Ductal AdenocarcinomaNon-small Cell Lung CancerColorectal Cancer+2 more
Eli Lilly and Company 750
Early research (Phase 1)Looking for participantsNCT07349537
What this trial is testing

Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors

Who this might be right for
Non-small Cell Lung Cancer (NSCLC)Colorectal Cancer (CRC)Pancreatic Adenocarcinoma+7 more
Revolution Medicines, Inc. 574
Testing effectiveness (Phase 2)Looking for participantsNCT07148128
What this trial is testing

Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.

Who this might be right for
Advanced or Metastatic KRAS-mutant Tumor in Pancreatic AdenocarcinomaAdvanced or Metastatic KRAS-mutant Tumor in Colorectal CancerAdvanced or Metastatic KRAS-mutant Tumor in Non Small Cell Lung Cancer+2 more
Auricula Biosciences Inc.
Testing effectiveness (Phase 2)Active Not RecruitingNCT05009329
What this trial is testing

JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation in China

Who this might be right for
NSCLCSolid Tumor
Allist Pharmaceuticals, Inc. 315
Early research (Phase 1)Active Not RecruitingNCT06235983
What this trial is testing

LY3537982 in Chinese Participants With Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumors
Eli Lilly and Company 12
Early research (Phase 1)Looking for participantsNCT07204340
What this trial is testing

TLN-372 in Advanced KRAS Mutant Solid Tumors

Who this might be right for
KRAS Mutant Solid Tumors
Treeline Biosciences, Inc. 240
Early research (Phase 1)Study completedNCT01986166
What this trial is testing

MEHD7945A and Cobimetinib in Patients With Locally Advanced or Metastatic Cancers With Mutant KRAS

Who this might be right for
Neoplasms
Genentech, Inc. 23
Testing effectiveness (Phase 2)Looking for participantsNCT05638295
What this trial is testing

Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial)

Who this might be right for
Advanced Malignant Solid NeoplasmMetastatic Malignant Solid Neoplasm
National Cancer Institute (NCI) 105
Early research (Phase 1)Ended earlyNCT03948763
What this trial is testing

MRNA-5671/V941 as Monotherapy and in Combination With Pembrolizumab (V941-001)

Who this might be right for
NeoplasmsCarcinoma, Non-Small-Cell LungPancreatic Neoplasms+1 more
Merck Sharp & Dohme LLC 70
Early research (Phase 1)Study completedNCT00955773
What this trial is testing

The GSK MEK Inhibitor GSK1120212 and Everolimus in Cancer Subjects

Who this might be right for
Cancer
GlaxoSmithKline 64
Testing effectiveness (Phase 2)Active Not RecruitingNCT03600883
What this trial is testing

A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)

Who this might be right for
KRAS p.G12C Mutant Advanced Solid Tumors
Amgen 713
Early research (Phase 1)UnknownNCT06006793
What this trial is testing

SY-5933 in Patients With Advanced Solid Tumors Harboring the KRAS p.G12C Mutation

Who this might be right for
Advanced Solid Tumor
Shouyao Holdings (Beijing) Co. LTD 50
Testing effectiveness (Phase 2)Looking for participantsNCT06500676
What this trial is testing

GFH375 in Patients With Advanced Solid Tumors With KRAS G12D Mutations

Who this might be right for
KRAS G12D MutationsAdvanced Solid Tumors
Genfleet Therapeutics (Shanghai) Inc. 407
Early research (Phase 1)Looking for participantsNCT06040541
What this trial is testing

Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

Who this might be right for
Non-small Cell Lung Cancer (NSCLC)Colorectal Cancer (CRC)Pancreatic Ductal Adenocarcinoma (PDAC)+1 more
Revolution Medicines, Inc. 604
Testing effectiveness (Phase 2)Ended earlyNCT06024174
What this trial is testing

BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors

Who this might be right for
Advanced Solid Tumors
Bristol-Myers Squibb 5
Early research (Phase 1)Looking for participantsNCT07455617
What this trial is testing

Study of ABO2102 in KRAS-Mutated Solid Tumors

Who this might be right for
Advanced / Metastatic Solid Tumor
Suzhou Abogen Biosciences Co., Ltd. 101
Early research (Phase 1)Study completedNCT03118817
What this trial is testing

Expansion Study to Evaluate the Efficacy and Safety of HM95573 in BRAF, KRAS or NRAS Mutant Solid Cancers

Who this might be right for
Solid Tumor
Hanmi Pharmaceutical Company Limited 65
Testing effectiveness (Phase 2)Study completedNCT06208124
What this trial is testing

IMM-6-415 in RAS/RAF Mutant Solid Tumors

Who this might be right for
Advanced Solid Tumor (Phase 1)Pancreas AdenocarcinomaNon-small Cell Lung Cancer+1 more
Immuneering Corporation 30
Early research (Phase 1)Looking for participantsNCT06586515
What this trial is testing

MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

Who this might be right for
Pancreatic Ductal AdenocarcinomaNon-small Cell Lung CancerColorectal Cancer
Eli Lilly and Company 630
Early research (Phase 1)Study completedNCT02022982
What this trial is testing

PALBOCICLIB + PD-0325901 for NSCLC & Solid Tumors

Who this might be right for
KRAS Mutant Non-Small Cell Lung CancerSolid Tumors
Dana-Farber Cancer Institute 60
Load More Results
110